Bioengineered Cardiac Tissue for Cardioyopathy Analysis


About this study

The purpose of this study is to produce and characterize patient-specific cardiac tissue for cardiomyopathy using reprogrammed cell technology. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients age 0-100 years.
  • Clinically diagnosed cardiomyopathy.
  • Unaffected biological family members.
  • Uunrelated healthy controls.
  • IRB# 13-00008 participants.

Exclusion Criteria:

  • Allergy to subcutaneous lidocaine, bupivicaine, or epinephrine. 

Eligibility last updated 11/22/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jay Schneider, M.D., Ph.D.

Closed for enrollment

Contact information:

Karen Miller CCRP

(507) 266-5510

More information


Publications are currently not available

Mayo Clinic Footer